Tigecycline Intravenous (Iv) Solution Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Solution
Available Strengths: 50 mg/2 mL, 100 mg/2 mL, 50 mg/100 mL, 100 mg/100 mL
Reference Brands: Tygacil(US)
Category:
Antibiotics
Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment. It provides broad-spectrum activity, including multidrug-resistant bacteria. Benefits include rapid bacterial eradication, effectiveness against complicated intra-abdominal and skin infections, and use in severe infections unresponsive to other antibiotics.
Tigecycline Intravenous (IV) Solution is available in Intravenous (IV) Solution
and strengths such as 50 mg/2 mL, 100 mg/2 mL, 50 mg/100 mL, 100 mg/100 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tigecycline Intravenous (IV) Solution is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tigecycline Intravenous (IV) Solution can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tigecycline IV is approved in the EU and US for complicated intra-abdominal and skin infections. In the EU, brands like Tygacil are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data; generic versions are available. Both regions require detailed dossiers, including clinical trial results, manufacturing standards, and pharmacovigilance plans, for approval and safety monitoring. Due to its broad-spectrum activity against resistant bacteria, strict prescribing controls are enforced. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access for tigecycline IV, ensuring adherence to European and US regulatory standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing